Calimmune gets AAV technology from AskBio
Asklepios BioPharmaceutical Inc. (AskBio) licensed Calimmune Inc. rights to its adeno-associated virus (AAV) gene vector delivery, self-complementary, and manufacturing technologies and know-how.
- Gene Therapy, Cell Therapy
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com